Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : AstraZeneca
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A study to investigate the analgesic efficacy of AZD2423 compared with placebo after 28 days treatment in patients with posttraumatic neuralgia
To investigate the analgesic efficacy of AZD2423 compared with placebo after 28 days of oral administration in patients with PTN.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A 24-Week, International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study to Evaluate the Efficacy and Safety of Dapagliflozin in Combination with Metformin compared with a DPP-4 inhibitor (Sitagliptin) in Combination with Metformin in Adult Patients with Type 2 Diabetes who have Inadequate Glycaemic Control on Metformin Therapy Alone
To examine whether, after 24 weeks of oral administration of double-blind treatment, the change from baseline in glycosylated haemoglobin A1c (HbA1c) level with dapagliflozin 10 mg plus metformin is n...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A Phase IIa randomised, double-blind, placebo controlled, parallel group, multicentre study evaluating the efficacy, safety, tolerability and pharmacokinetics of AZD1386 after 3 weeks of treatment in patients with Posttraumatic Neuralgia (PTN) and Postherpetic Neuralgia (PHN)
To evaluate the analgesic efficacy of 21 days of oral administration of AZD1386 compared to placebo in patients with Post Traumatic Neuralgia (PTN) or Post Herpetic Neuralgia (PHN) with mechanical hyp...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
AstraZeneca SAS
MAJ Il y a 5 ans
A randomized, double-blind phase II trial to assess the efficacy and safety of bicalutamide (Casodex® ) associated to ZD6474 (Zactima™ ) or to placebo in patients with castration-refractory metastatic prostate cancer without any clinical symptom related to disease progression
To assess the effect of ZD6474 (Vandetanib, Zactima™ ) on time to prostate specific antigen (PSA) progression (TTP) in patients with castration-refractory metastatic prostate cancer, without any clini...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A Phase II, Multi-centre, Open-Label, Parallel Group, Randomised Study To Compare the Efficacy of AZD6244 vs Temozolomide in Patients with Unresectable AJCC Stage 3 or 4 Malignant Melanoma
To compare the efficacy of AZD6244 vs temozolomide in patients with unresectable AJCC stage 3 or 4 malignant melanoma
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase II study to Assess the efficacy of 28 Day Oral Administration of AZD1236 in Adult Patients with Cystic Fibrosis
The primary objective is to investigate whether AZD1236 shows evidence of efficacy in CF patients by: • investigation of biomarkers (MMP-9 levels and TNF-α) in induced sputum • study signs and symptom...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A single-dose study to investigate the effects of 4 different doses of inhaled AZD8683 in COPD patients
To investigate the bronchodilatory effects of 4 different single doses of inhaled AZD8683 compared with placebo, with respect to peak and trough forced expiratory volume in the first second (FEV1), in...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
Study comparing complete remission after treatment with selumetinb/palcebo in patients with differentiated thyroid cancer Studio che confronta la remissione completa dopo il trattamento con selumetinib / placebo in pazienti con tumore differenziato della tiroide
To compare the efficacy of selumetinib with radioactive iodine therapy (RAI), versus placebo with RAI, by assessment of complete remission rate at 18 months post RAI treatment in the overall study pop...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
CHANT (Cerebral Hemorrhage And NXY Treatment) A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase IIb study to assess the safety and tolerability of 72 hours intravenous infusion of NXY 059 in adult patients with acute intracerebral hemorrhage (ICH)
The primary objective of this study is to assess the safety and tolerability of NXY-059 compared to placebo in patients with acute ICH by assessment of mortality (overall and by cause), the incidence ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A 4 week double-blind, placebo-controlled, randomized, parallel group phase IIa study to assess the efficacy and safety of AZD1981 in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)
The primary objective is to evaluate the efficacy of AZD1981 as compared with placebo in patients with moderate to severe COPD.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
13
14
15
16
17
18
19
20
21
22
Suivant